Table 1.
Summary of PSs approved for clinical application [34].
| PS | Excitation wavelength | Approved | Indication |
|---|---|---|---|
| Porfimer sodium/PF® | 630 nm | Worldwide, withdrawn in EU for commercial reasons | Severe dysplasia in Barrett's esophagus. Obstructive esophageal or lung cancer |
| 5-ALA/Ameluz®/Levulan® | 635 nm | Worldwide | Mild to moderate actinic keratosis |
| Metvix®/Metvixia® | 570–670 nm | Worldwide | Non-hyperkeratotic actinic keratosis and basal cell carcinoma |
| Temoporfin/mTHPC/Foscan® | 652 nm | Europe | Advanced head and neck cancer |
| Talaporfin/NPe6/Laserphyrin® | 664 nm | Japan | Early centrally located lung cancer |
| Verteporfin/Visudyne® | 690 nm | Worldwide | AMD |
| Redaporfin®/LUZ11 | 749 nm | Orphan status in EU | Biliary tract cancer |
| Synthetic hypericin/SGX301 | 570–650 nm | Orphan status in EU | Cutaneous T-cell lymphoma |
PS, photosensitizer; PF, photofrin; AMD, age-related macular degeneration; NP, nanoparticle; EU, European Union; mTHPC, meta-tetra (hydroxyphenyl) chlorine.